Conference report: Positive data presented from final phase II trial of trilaciclib in combination with chemotherapy in metastatic triple-negative breast cancer

Trial (n=102) reported improved overall survival for patients treated with the two dose regimens of trilaciclib, a 1st-in-class short-acting CDK4/6 inhibitor; in combination with gemcitabine/carboplatin (GC) vs. GC alone (not reached and 17.8 months vs. 12.6 months, respectively.

Biospace Inc.